Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 feasibility and safety study of rhBMP-2/CPM as an adjuvant therapy for proximal femur fractures
2006-001832-34Phase 2Completed
- Sponsor
- Wyeth
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of dibotermin alfa in hip fracture (3 arms), sponsored by Wyeth. Primary endpoints: Incidence of secondary fracture displacement, Fracture healing and 2 more. Started Sep 2006; status: completed.
02
Drugs
dibotermin alfa
03
Conditions
hip fracture
Beyond the preview
Go deeper on 2006-001832-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001832-34.